Valiant Organics Ltd Q1 FY2024 Concall Summary

Key Takeaways

• A brutal quarter, guidance slashed: Standalone revenue guidance was cut from INR 1,200 crore to INR 800-850 crore, and EBITDA margin guidance from 20% to 12%, as a confluence of China dumping, agro slowdown, and inventory destocking drove a 24% YoY revenue decline.
• China is the dominant headwind: Excess Chinese production is being sold at raw material cost, crashing prices by 25-30% across PAP, chlorophenols and dyes, with no timeline for when this dumping will end.
• PAP ramp-up is the critical internal fix: The flagship PAP project is running at sub-optimal output due to a process change from continuous to semi-continuous; management believes crossing the 500-600 tons per month barrier will resolve issues, but markets must also support the volume.
• Debt costs are compounding the pain: Capitalized interest from the newly commercialized Pharma Intermediate plant has hit the P&L, causing a sudden jump in interest costs on top of rising rates over the last 1.5-2 years.
• What to watch next quarter: Whether PAP volumes cross 400-500 tons per month as targeted, any stabilization in price corrections, and whether the expected Q3 textile recovery shows early signs in client order patterns.

Demand & Pricing Environment

• Demand collapse is broad-based: Sluggishness in dyes and pigments continued from prior quarters, and a new slowdown emerged in agrochemicals, further weakening an already stressed demand environment.
• China dumping is crushing prices: All chemistries are affected, with chlorophenols relatively less impacted; prices have corrected 25-30% across the basket, and Chinese producers are reportedly selling at raw material cost to destock excess inventory.
• Volume and price both down: The 30% revenue degrowth splits roughly into a 14-15% volume decline and a 10% price decline across the product basket, with capacity utilization running at just 50%.
• Raw materials have bottomed: Raw material prices have stabilized and some have started seeing an uptick, but top-line prices continue to move down fast, squeezing the benefit.
• No quick China resolution: Management offered no timeline for when dumping will end, noting it could take 2-3 years; the cycle's magnitude is unprecedented, with multiple factors (COVID, euro crisis, Ukraine-Russia, fuel prices, Sarigam blast) coinciding for the first time.

Shah: "Something of this sort at this magnitude is first time, because there is a lot of factors came in together. Every time there was one reason why the issue was there. This time at least two-three reasons why the whole slowdown has come in."

PAP & OAP: The Growth Engines That Stalled

• PAP process change disrupted output: The plant was shifted from a fully continuous to a semi-continuous batch process to achieve desired product quality; optimum output has not yet been reached, and a June expansion shutdown further hit Q1 volumes.
• The 500-600 ton threshold: Management believes that once monthly production crosses this barrier, issues will self-mitigate; the target is to reach 400-500 tons per month from Q2 and 600 tons by year-end, but this depends on market support.
• PAP revenue guidance slashed: Earlier guidance of INR 300 crore for FY24 has been revised down to INR 170-180 crore, maximum INR 200 crore, reflecting both the ramp-up delays and price erosion.
• OAP is still experimental: OAP faces similar quality issues to PAP's early days, specifically around eliminating certain impurities; no commercialization timeline is available, and if it does contribute this year, it will be in the range of INR 30-35 crore on a full-year basis.
• Technical fixes identified: Process changes for PAP have been identified and proven successful at test-run level; implementation is expected in a couple of months.

Shah: "Once we crossed the 500-600 tons per month barrier, then it should kind of mitigate by itself."

Margins & Cost Structure

• Gross margin improved YoY but squeezed QoQ: Standalone gross margins rose from 30.30% to 35.49% YoY, but the sequential squeeze reflects the rapid top-line decline outpacing cost adjustments.
• Interest cost spike: Interest rates have been rising over the last 1.5-2 years, and additionally, interest that was capitalized during the Pharma Intermediate plant's construction phase has now hit the P&L after commercialization, causing a sudden jump.
• Cost-cutting is operational, not structural: The company has rationalized contract workers, revisited overtime and wage expenses, invested in a renewable captive plant (INR 2.5-3 crore annual benefit), and is introducing DCS systems for automation; however, management does not see employee costs coming down at a full company level.
• CapEx returns are deferred, not abandoned: Management insists the CapEx that has gone in must give returns once market dynamics improve; current plans may see some spillover into Q1 next year but are not being reconsidered.

New Projects & Diversification

• Pharma Intermediates commercialized: The plant is now in its starting phase and expected to contribute INR 60-65 crore on a full-year basis; Q1 contribution was negligible.
• New chlorination molecule introduced: A new molecule has been added in chlorination; not as large as PAP but intended to diversify the product portfolio.
• Wind power plant operational: A 2.2-megawatt captive wind power plant has been commercialized alongside Renew Power; benefits will begin flowing from Q2 FY24 onwards.
• Ataali land acquired for chlorination: Land has been purchased for chlorination expansion, with a direct pipeline connection to chlorination plants, improving logistics; the purchase was partly funded by the sale of another land parcel.
• Valiant Laboratories IPO pending: The DRHP has been filed and the subsidiary is awaiting approvals; management declined to comment on timing or expansion details.

Balance Sheet & Capital Allocation

• Debt peak not yet reached: Management is not currently considering significant additional debt but will revisit in a couple of months depending on market movements and CapEx cash flow requirements.
• Existing term loans amortizing: Current term loans will become zero by FY26, providing some medium-term relief on interest costs.
• Land sale proceeds: A small land parcel in Dahej was sold (the company decided not to expand there), and another parcel was sold to fund the Ataali land purchase; the Sayakha land was sold to subsidiary Valiant Laboratories for their expansion.
• No buyback, no share price support: Management explicitly declined to comment on the share price drop from INR 2,000 to INR 380-400 and ruled out a buyback to boost confidence.
• Promoter shareholding opacity: An analyst flagged that public shareholding which is actually promoter-held is not being reclassified; management acknowledged the point but had no answer, and declined to comment on potential further promoter dilution.

Guidance & Commitments

Key Metrics